A head-to-head study comparing five serological assays for SARS-CoV-2 antibodies showed that a commercial immunoassay by Siemens and a novel ELISA* test developed by the University of Oxford could achieve the desired sensitivity and specificity without further optimization — providing reassurance for their use.
Hospitalized COVID-19 patients with prolonged fever showed more pronounced inflammatory response and were more likely to require ICU admission than cases with saddleback fever or with fever lasting ≤7 days, a Singapore study reveals.
As high as 40 percent of the healthcare workers (HCWs) infected with COVID-19 were asymptomatic, raising concerns on silent transmission in the healthcare settings, according to a systematic review and meta-analysis released during ECCVID 2020.
Regular, low-dose, oral sustained-release morphine improved the health status of patients with moderate-to-very-severe chronic breathlessness due to chronic obstructive pulmonary disease (COPD), the MORDYC* trial has shown, validating its palliative role for chronic breathlessness.
Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.